Online Program Home
  My Program
CC = Baltimore Convention Center,    H = Hilton Baltimore
* = applied session       ! = JSM meeting theme

Activity Details

243 Mon, 7/31/2017, 2:00 PM - 3:50 PM CC-Halls A&B
Contributed Poster Presentations: Biopharmaceutical Section — Contributed Poster Presentations
Biopharmaceutical Section
Chair(s): Jessi Cisewski, Yale University
17: Event Rate Estimation Based on Blinded Time-To-Event Data to Verify Sample Size Calculation Assumptions Youlan Rao, United Therapeutics Corporation, Durham, NC ; Suhyun Kang, North Carolina State University, Raleigh, NC ; Jody Cleveland, United Therapeutics Corporation, Durham, NC ; Chunqin Deng, United Therapeutics Corporation, Durham, NC
18: Generalized Youden's Index to Derive the Optimal Thresholds for Discriminant Analysis Kelly H. Zou, Pfizer Inc ; Ching-Ray Yu, Pfizer Inc ; Jason Pan, Pfizer Inc ; Dhaval Patel, Pfizer Inc ; Martin Carlsson, Pfizer Inc
19: Sample Size Calculation in Clinical Trials with Binary Co-Primary Endpoints or Multiple Testing Procedures Zuoshun Zhang, Celgene Corporation
20: Survival Prediction in Early-Stage Lung Cancer via Bayesian Model Averaging of Nonparametric Accelerated Failure Time Models Kijoeng Nam, Merck ; Nicholas Henderson, Johns Hopkins University ; Dai Feng, Merck
21: An Evaluation of Multiple Imputation Methods for Hierarchical Data Takayuki Abe, Keio University School of Medicine ; Manabu Iwasaki, Seikei University
22: A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades Sungjin Kim, Cedars-Sinai Medical Center ; Marcio Diniz, Cedars Sinai Medical Center ; Mourad Tighiouart, Cedars-Sinai Medical Center
23: Constrained Longitudinal Model for Analyzing Pre- and Post-Treatment Count Data Yongming Qu, Eli Lilly and Company ; Junxiang Luo, Eli Lilly and Company ; Hong Zhao, Abbott Laboratories
24: A Curtailed Design for Selecting the t Best Among Bernoulli Treatments and a Control Mingyue Wang, Syracuse University ; Pinyuen Chen, Syracuse University
25: Two-Stage Design for Phase II Cancer Clinical Trials with Multiple Endpoints Hui Gu, Rutgers University ; Yong Lin, Rutgers ; Weichung Joe Shih, Rutgers School of Public Health ; Yaqun Wang, Rutgers ; Kejian Liu, Celgene
26: Drug Combination Dose Allocation Using Minimal Sets and Coherence in Partially Ordered Sets in Phase I Cancer Trials Galen Cook-Wiens, Cedars Sinai Medical Center ; Matthieu Clertant, Cedars-Sinai Medical Center ; Mourad Tighiouart, Cedars-Sinai Medical Center
27: Interim Analysis with Short-Term and Long-Term Endpoint in Adaptive Group Sequential Design Lin Pan, ICON PLC ; Jill Stankowski, ICON PLC
28: Sample Size Calculation Based on Finite Mixture Model Zejiang Yang, INC Research
29: Local Odds Ratio Is More Efficient Than Correlation Coefficient For Modeling Longitudinal Ordinal Data Xinkai Zhou, Statistics Core@UCLA ; Ronghui Xu, University of California, San Diego ; David Elashoff, University of California, Los Angeles
30: Modeling Excess Zeroes in an Integrated Analysis of Vaccine Safety Roger Maansson, Pfizer Inc. ; David Radley, Pfizer Inc. ; Qin Jiang, Pfizer Inc. ; Scott Patterson, Pfizer Inc. ; Judith Absalon, Pfizer Inc. ; John Perez, Pfizer Inc.
31: Using an Onset-Anchored Bayesian Hierarchical Model to Improve Predictions for Amyotrophic Lateral Sclerosis Disease Progression Alex Karanevich
32: What Is the Best Design for Dose-Finding Trials with Small Number of Doses? Lai Wei ; Julie Stephens, The Ohio State Univeristy ; Vedat Yildiz, The Ohio State University ; Marilly Palettas, The Ohio State University ; Songzhu Zhao, The Ohio State University ; Xueliang Pan, The Ohio State Univeristy
33: An R Shiny Foundation for Standardized Clinical Review Tools Jimmy Wong, FDA
34: Analysis Timing in Oncology Immunotherapy Trials with a Late Separation of Overall Survival Curve Shu-Chih Su, Merck
35: Analysis of Adverse Event Relationships in Clinical Trials Using JMP Anastasia Dmitrienko ; Kelci Miclaus, JMP Life Sciences, SAS Institute Inc. ; Richard C. Zink, JMP Life Sciences, SAS Institute, Inc.
37: Sample Size Re-Estimation and Other Midcourse Adjustments with Sequential Parallel Comparison Design Rachel Silverman, University of North Carolina ; Anastasia Ivanova, UNC at Chapel Hill
38: A Modified LOCF-PMM Method with Multiple Imputation for Handling Missing Data in Longitudinal Studies Busola Sanusi, The University of North Carolina at Chapel Hill ; Kenneth Liu, Merck & Co. ; Gregory Golm, Merck & Co., Inc.
40: A Simulation Study to Evaluate the Performance of Different Exposure Response Analyzes Using Concentration-QTc Data Dalong Huang, FDA
41: Sensitivity Analysis of Andersen-Gill Model Dongmei Lan ; Jill Stankowski, ICON PLC
42: Design of Drug Combination Early Phase Cancer Trials Using Time to Toxicity Data Marcio Diniz, Cedars Sinai Medical Center ; José Jimenez, Politecnico di Torino ; Andre Rogatko, Cedars Sinai Medical Center ; Mourad Tiguiouart, Cedars Sinai Medical Center
43: Emax Modeling for Assessing Dose-Response Relationships Using JMP Beibo Zhao, University of North Carolina at Chapel Hill ; Richard C. Zink, JMP Life Sciences, SAS Institute, Inc.
46: Quantitative Analysis of Spreading Defects and Response to Therapeutics in Lowe Syndrome Brittany Griggs, Purdue University ; Swetha Ramadesikan, Purdue University ; Ruben Claudio Aguilar, Purdue University
48: Comparing Two Correlated ROC Curves: a Generalized Pivotal Quantity Approach Yonggang Zhao, Skyview Research ; Qianqiu Li, Johnson and Johnson
49: dECiDe: software developed by Cytel and AstraZeneca for early clinical study design Patrick D. Mitchell, Early Clinical Development AstraZeneca ; Dominic Magirr, AZ IMED Biotech Unit, ECD Biometrics ; Elizabeth Pilling, AZ IMED Biotech Unit, ECD Biometrics ; James Matcham, AZ IMED Biotech Unit, ECD Biometrics ; Jaydeep Bhattacharyya, Cytel Inc. ; Charles Liu, Cytel Inc.
Copyright © American Statistical Association